MedTrace Logo

Safety and Efficacy Study of Oral Zabofloxacin in Community Acquired Pneumonia

NCT01081964 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2012-05-07

No results posted yet for this study

Summary

A double-blind, three-arm study, to evaluate the safety and efficacy of two dosing regimens of zabofloxacin (a fluoroquinolone antibiotic) in community acquired pneumonia.

Conditions

  • Community Acquired Pneumonia

Interventions

DRUG

Zabofloxacin

Zabofloxacin 400mg capsule once daily for 3 days

DRUG

Levofloxacin 500mg

Levofloxacin 500mg orally for 7 days

DRUG

Zabofloxacin 400mg

Zabofloxacin 400mg orally for 5 days

Sponsors & Collaborators

  • IASO Pharma Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-03-31
Primary Completion
2012-04-30
Completion
2012-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01081964 on ClinicalTrials.gov